The management of six awake, spontaneously breathing patients with acute severe asthma who responded to a subanesthetic dose of an inhalational agent is described. All of these patients were on maximal medical treatment, the next intervention likely to be tracheal intubation and mechanical ventilation in the face of further deterioration. All six patients initially responded dramatically, although one required mechanical ventilation after initial response.
Refractory asthma in ventilated patients has been shown to respond well to inhaled halothane 1, 2 . A case has previously been described where sub-anaesthetic doses of halothane relieved bronchospasm in an awake patient who was refractory to maximal conventional therapy 3 . A further five asthmatic patients are now described where the aim was to relieve the bronchospasm and therefore avoid mechanical ventilation and its associated complications 4 .
CASE HISTORIES
All six patients were previously diagnosed as having severe asthma and five had required ventilation in the past. The patients were all hypertensive, tachycardic and very distressed. Despite breathing 15 litres.min -1 of oxygen via a non-rebreathing mask, four of the six had a P a O 2 of less than 66 mmHg. Following referral and admission to intensive care unit, standard asthma treatment was continued. Each patient was receiving six hourly boluses of 100 mg intravenous hydrocortisone and was on regular salbutamol (5 mg) and ipratropium bromide (500 µg) nebulizers. They had all been loaded with intravenous aminophylline 6 mg.kg -1 and were receiving an infusion of 0.5 mg.kg -1 .h -1 . Daily theophylline levels were done. Finally each patient had also been commenced on a terbutaline infusion up to 5 µg.min -1 . Preparation for intubation and ventilation was made with all the necessary drugs and equipment. In five of the patients halothane up to 0.5% in 100% oxygen, was slowly introduced via a Bain circuit using a Tech 3 vaporizer mounted on a Boyle machine. The sixth patient received 0.25% sevoflurane in 100% oxygen.
All six patients responded well and repeat blood gases 15 minutes after commencing halothane are tabulated below ( Table 1 ). The four hypoxic patients all improved and only one became frankly hypercapnic, which resolved with decreasing halothane. The most impressive clinical sign was the rapid disappearance of the wheeze. We initially secured the mask using a Klaussens harness, but changed our technique to let the patients hold the mask, allowing feedback and preventing oversedation. The patients in fact were quite happy to administer the volatile agents themselves providing an excellent safety mechanism to avoid over-sedation.
The average length of time for which the patients required the halothane was 72 minutes (45 min-173 min). The patient who received the sevoflurane used it for 35 minutes. Five of the patients required only one period of therapy, but in one patient bronchospasm recurred 10 hours after initially stopping therapy. When her bronchospasm returned we elected to ventilate her as we did not want to use halothane again within such a short period because of the theoretical risk of halothane hepatitis.
A dose of 0.5% halothane provided the best balance between bronchodilation and oversedation. We were always able to maintain contact with the patients. The mean length of intensive care admission was 3.5 days for the patients who received halothane. The patient who received sevoflurane was discharged from the intensive care the following day. The five who responded were all discharged home less than 72 hours after the halothane was commenced.
Only one patient developed complications. This patient, who was aminophylline-toxic, developed runs of ventricular ectopics during the fourth episode of halothane use. The aminophylline infusion was stopped and the halothane only re-introduced when levels returned to normal. At no time was cardiovascular stability compromised.
DISCUSSION
Most asthmatics who are admitted to hospital respond to medical management. As few as 2.3% require mechanical ventilation 5 . Mortality rates quoted for mechanical ventilation may be as high as 38% 6 , with complication rates in survivors as high as 85.7% 5 .
The bronchodilator action of halothane has been well documented, but the mechanism of this action is still unknown. Its use as a bronchodilator in anaesthesia is well established and halothane has been used with success in ventilated patients with acute severe asthma who have not responded to usual medical management 1 . There are two mechanisms that might explain any clinical improvement in acute severe asthma with inhaled halothane. A bronchodilator effect is likely, though some improvement may be seen secondary to sedation and anxiolysis.
Kilde and Aviado concluded that halothane produced brochodilation by direct stimulation of beta-receptors 7 . Although commonly quoted this mechanism of action has been challenged 8 as betablocking drugs do not attenuate halothane's affect. These investigators concluded that halothane's bronchodilatory action was due to blocking of vagal reflexes and not due to beta-adrenergic stimulation.
The sedative and anxiolytic effect of halothane may also have a very marked clinical effect in acute severe asthma and even a centrally mediated fall in airways resistance. All of our patients were moderately sedated, indeed pleasantly so. The newer agent sevoflurane has also been shown to relieve bronchospasm 9 , and its mechanism of action is probably similar to that of halothane.
The arrhythmogenicity caused by simultaneous use of halothane and aminophylline is well known 10 . By keeping the levels of aminophylline in the therapeutic range this is minimised. The additional risk of halothane hepatitis may make sevoflurane a better alternative. Ketamine, magnesium and helium are novel therapies that have also been used to treat asthma. Ketamine can be used for the management of asthmatic patients, both for induction prior to intubation as well as to relieve resistant bronchospasm 11 . Magnesium has been used to relieve bronchospasm 12 and helium-driven ventilators have been evaluated, but have not been shown to make a clinical improvement 13 .
I have described the management of six patients with acute severe asthma who I believe have responded to the bronchodilator effect of halothane and sevoflurane and were all, at least initially, spared mechanical ventilation. Although the agents used are general anaesthetics the levels were kept low, the patients were carefully monitored and preparation for emergency intubation had been made.
Further studies are required to clarify the role of inhaled anaesthetic agents in awake patients with acute severe asthma. 
